Milner Therapeutics Institute welcomes three new UK Academic Partner Institutions
A key goal of the Milner from the outset has been to drive new models for academic-industry collaborations, and to lower barriers to engagement across these sectors. While the Milner Therapeutics Consortium is rooted in the Cambridge ecosystem – providing a hub for...
TRIMTECH Therapeutics expands from Milner Bio-incubator to Babraham Research Campus
Cambridge’s biotech ecosystem is built on progression – from early discovery through to scale. As TRIMTECH expands out of the Milner Therapeutics Institute’s Bio-incubator and into the Babraham Research Campus, we are pleased to reflect on their journey so far. ...
Milner Therapeutics Institute and Cambridge Enterprise welcome Curie.Bio to Cambridge
Last week, we joined forces with Cambridge Enterprise to welcome Curie.Bio to Cambridge – a venture capital firm that helps founders discover and develop important new medicines. We began the day by welcoming Curie.Bio leadership at the Milner Therapeutics Institute...
Immutrin raises £65 million in Series A funding to advance amyloidosis therapy
We’re delighted that Milner Institute Bio-incubator company Immutrin has announced the successful close of a £65 million ($87 million) Series A financing round to develop a next-generation antibody therapy for ATTR amyloidosis. This funding will enable Immutrin to...